Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evofosfamide + Zalifrelimab + Balstilimab in Advanced Solid Malignancies
NCT06782555Phase 2
Key facts
- Status
- Active, not recruiting
- Start
- Jan 2025
- Primary completion
- Oct 2027
- Countries
- 1
- Sponsor
- ImmunoGenesis
- Modality
- Small Molecules
- Drugs
- evofosfamide
- Conditions
- castration-resistant prostate cancer (CRPC)pancreatic cancer (PC)squamous cell carcinoma of the head and neck (HNSCC)
01
Overview
Phase 2, open-label trial of evofosfamide in castration-resistant prostate cancer (CRPC), pancreatic cancer (PC) and squamous cell carcinoma of the head and neck (HNSCC), sponsored by ImmunoGenesis. Started Jan 2025; status: active, not recruiting.
02
Design
- Study design
- Non-randomizedOpen-label
03
Registry description
The purpose of this Phase 1/2 study is to test the overall safety, tolerability, and effectiveness of the combination investigational drugs evofosfamide, zalifrelimab, and balstilimab in treating advanced or metastatic castration-resistant prostate cancer, pancreatic cancer, and human papilloma virus (HPV)-negative squamous cell carcinoma of the head and neck (SCCHN).
Beyond the preview
Go deeper on NCT06782555.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06782555.